Oyster Point Pharma

The company was founded in 2015.

In October 2021, Tyrvaya was the first nasal spray approved by Food and Drug Administration to treat dry eye syndrome.^[3] This became the company's lead product.

Prior to going public, Oyster Point Pharma operated at a loss of $16.5 million in 2018.^[4]

In February 2019, still at clinical stage, the company raised $93 million in its Series B funding round.^[5][6]

In October 2019, the company issued 5-million shares in the initial public offering with NASDAQ Global Select Market at the price of $16 per share with the first trading day on October 31.^[7] In January 2023 Viatris acquired Oyster Point Pharma in an all-cash deal.^[8]